National pharmacological policy should be aimed at substantiated selection and rational use of medicinal drugs in order to ensure affordable, high-quality, efficient and safe pharmacotherapy. Primary openangle glaucoma (POAG) is still among the most common ophthalmic pathologies, characterized by steady increase in incidence. Therefore, the society is facing a challenge of optimizing costs for POAG pharmacotherapy, which should be addressed at the nation level. We have identified antiglaucoma medicines, recommended for inclusion in formulary and insurance lists, namely, Timolol, Latanoprost and Travoprost ophthalmic solutions for monotherapy, and combinations of antiglaucoma mono-drugs such as Arutimol 0.5% and Taflotan, Arutimol 0.5% and Lanotan, Azopt and Taflotan based on the results of complex marketing and pharmacoeconomic studies. The introduction of partial reimbursement of the cost of these medicines for patients with POAG will bring them more opportunities for using highly efficient and safe medicines from S01E Group" Antiglaucoma medicines and miotics" under conditions of limited funding of medical and pharmaceutical industries. Particular attention is drawn to the availability of domestic medicine Lanotan eye drops, 0.05 mg/ml, 2.5 ml number 1 produced by OJSC Farmak (Ukraine) among those recommended for inclusion in FL and IL as both a monotherapy for POAG and a part of treatment regimens that combine several AGMs.